We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Amneal Pharmaceuticals (AMRX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Amneal Pharmaceuticals is a member of the Medical sector. This group includes 916 individual stocks and currently holds a Zacks Sector Rank of #8. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Amneal Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for AMRX's full-year earnings has moved 3.6% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, AMRX has moved about 66.8% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 5.1% on a year-to-date basis. This means that Amneal Pharmaceuticals is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Iovance Biotherapeutics (IOVA - Free Report) . The stock is up 404.8% year-to-date.
The consensus estimate for Iovance Biotherapeutics' current year EPS has increased 25.1% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Amneal Pharmaceuticals belongs to the Medical - Drugs industry, a group that includes 133 individual stocks and currently sits at #80 in the Zacks Industry Rank. On average, this group has lost an average of 3.8% so far this year, meaning that AMRX is performing better in terms of year-to-date returns.
In contrast, Iovance Biotherapeutics falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 449 stocks and is ranked #104. Since the beginning of the year, the industry has moved +5%.
Investors interested in the Medical sector may want to keep a close eye on Amneal Pharmaceuticals and Iovance Biotherapeutics as they attempt to continue their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Amneal Pharmaceuticals (AMRX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Amneal Pharmaceuticals is a member of the Medical sector. This group includes 916 individual stocks and currently holds a Zacks Sector Rank of #8. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Amneal Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for AMRX's full-year earnings has moved 3.6% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, AMRX has moved about 66.8% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 5.1% on a year-to-date basis. This means that Amneal Pharmaceuticals is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Iovance Biotherapeutics (IOVA - Free Report) . The stock is up 404.8% year-to-date.
The consensus estimate for Iovance Biotherapeutics' current year EPS has increased 25.1% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Amneal Pharmaceuticals belongs to the Medical - Drugs industry, a group that includes 133 individual stocks and currently sits at #80 in the Zacks Industry Rank. On average, this group has lost an average of 3.8% so far this year, meaning that AMRX is performing better in terms of year-to-date returns.
In contrast, Iovance Biotherapeutics falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 449 stocks and is ranked #104. Since the beginning of the year, the industry has moved +5%.
Investors interested in the Medical sector may want to keep a close eye on Amneal Pharmaceuticals and Iovance Biotherapeutics as they attempt to continue their solid performance.